CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study
Genetic susceptibility could be modified by environmental factors and may also influence differential responses to treatments for age-related macular degeneration (AMD). We investigated whether genotype could influence response to docosahexaenoic acid (DHA)-supplementation in the occurrence of choro...
Gespeichert in:
| Veröffentlicht in: | PloS one 2015-07, Vol.10 (7), p.e0130816-e0130816 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0130816 |
|---|---|
| container_issue | 7 |
| container_start_page | e0130816 |
| container_title | PloS one |
| container_volume | 10 |
| creator | Merle, Bénédicte M J Richard, Florence Benlian, Pascale Puche, Nathalie Delcourt, Cécile Souied, Eric H |
| description | Genetic susceptibility could be modified by environmental factors and may also influence differential responses to treatments for age-related macular degeneration (AMD). We investigated whether genotype could influence response to docosahexaenoic acid (DHA)-supplementation in the occurrence of choroidal new vessels (CNV).
The Nutritional AMD Treatment 2 (NAT2) study was a randomized, placebo-controlled, double-blind, parallel, comparative study, including 250 patients aged 55 to 85 years with early lesions of age-related maculopathy, visual acuity better than 0.4 Logarithm of Minimum Angle of Resolution units in the study eye and neovascular AMD in the fellow eye. Patients were randomized at baseline to receive either 3 daily fish-oil capsules, each containing 280 mg DHA, 90 mg EPA and 2 mg Vitamin E, or placebo.
Patients carrying the risk allele (C) for CFH Y402H had no statistically significant increased risk for developing CNV in the study eye (Hazard Ratio (HR)=0.97; 95% Confidence Interval (CI): 0.54-1.76 for heterozygous and HR=1.29; 95%CI: 0.69-2.40 for homozygous). Patients carrying the risk allele (T) for ARMS2 A69S had no statistically significant increased risk for developing CNV in the study eye (HR=1.68; 95%CI: 0.91-3.12) for heterozygous and HR=1.78; 95%CI: 0.90-3.52 for homozygous). A significant interaction was observed between CFH Y402H and DHA-supplementation (p=0.01). We showed a protective effect of DHA-supplementation among homozygous non-risk patients. Among these patients, occurrence of CNV was 38.2% in placebo group versus 16.7% in DHA group (p=0.008).
These results suggest that a genetic predisposition to AMD conferred by the CFH Y402H variant limits the benefit provided by DHA supplementation.
ISRCTN registry 98246501. |
| doi_str_mv | 10.1371/journal.pone.0130816 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1692759717</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A420144559</galeid><doaj_id>oai_doaj_org_article_1d246b9907ee46be8799a6eb89dd7ac1</doaj_id><sourcerecordid>A420144559</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-12466d2df536bbf176ef6367207669521dd2f8423495648ccd846c30f18b1ccc3</originalsourceid><addsrcrecordid>eNqNk9tu1DAQhiMEoqXwBggsISG42CU-xIm5QIpaylbqSd2CxJXltScbV068xElpX4cnxXto1UW9QL4Ya-ab356xJ0le43SMaY4_Xfmha5UbL3wL4xTTtMD8SbKLBSUjTlL69MF-J3kRwlWaZrTg_HmyQzimJM3FbvJn_3CCfrKUTJBqDSovTqYElVxM0bl3t43vFrUNTVgFzzrl0HRYLBw00Paqt75Fv21fowOvfVA13ChovdWo1NYg26JT8Ncq6MGpDpVzGF2AUz0YdKLWvgOYQwvdWuk8migbPqPLGtBpeUnQtB_M7cvkWaVcgFcbu5d8P_x6uT8ZHZ99O9ovj0eaC9KPMGGcG2KqjPLZrMI5h4pTnsc6ORcZwcaQqmCEMpFxVmhtCsY1TStczLDWmu4lb9e6C-eD3LQ3SBzV80zkOI_E0ZowXl3JRWcb1d1Kr6xcOXw3l6rrrXYgsYnXmQmR5gBxA0UuhOIwK4QxudI4an3ZnDbMGjA6Vh7buyW6HWltLef-WjJWCCZoFPiwEej8rwFCLxsbNDinWvDD6t40J1wIHtF3_6CPV7eh5ioWYNvKx3P1UlSWjKSYsSwTkRo_QsVloLE6_sXKRv9WwsethMj0cNPP1RCCPJpe_D979mObff-ArUG5vg7eDcu_FLZBtgZ150PooLpvMk7lcpTuuiGXoyQ3oxTT3jx8oPuku9mhfwG9SxeZ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1692759717</pqid></control><display><type>article</type><title>CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Merle, Bénédicte M J ; Richard, Florence ; Benlian, Pascale ; Puche, Nathalie ; Delcourt, Cécile ; Souied, Eric H</creator><contributor>Mori, Keisuke</contributor><creatorcontrib>Merle, Bénédicte M J ; Richard, Florence ; Benlian, Pascale ; Puche, Nathalie ; Delcourt, Cécile ; Souied, Eric H ; Mori, Keisuke</creatorcontrib><description>Genetic susceptibility could be modified by environmental factors and may also influence differential responses to treatments for age-related macular degeneration (AMD). We investigated whether genotype could influence response to docosahexaenoic acid (DHA)-supplementation in the occurrence of choroidal new vessels (CNV).
The Nutritional AMD Treatment 2 (NAT2) study was a randomized, placebo-controlled, double-blind, parallel, comparative study, including 250 patients aged 55 to 85 years with early lesions of age-related maculopathy, visual acuity better than 0.4 Logarithm of Minimum Angle of Resolution units in the study eye and neovascular AMD in the fellow eye. Patients were randomized at baseline to receive either 3 daily fish-oil capsules, each containing 280 mg DHA, 90 mg EPA and 2 mg Vitamin E, or placebo.
Patients carrying the risk allele (C) for CFH Y402H had no statistically significant increased risk for developing CNV in the study eye (Hazard Ratio (HR)=0.97; 95% Confidence Interval (CI): 0.54-1.76 for heterozygous and HR=1.29; 95%CI: 0.69-2.40 for homozygous). Patients carrying the risk allele (T) for ARMS2 A69S had no statistically significant increased risk for developing CNV in the study eye (HR=1.68; 95%CI: 0.91-3.12) for heterozygous and HR=1.78; 95%CI: 0.90-3.52 for homozygous). A significant interaction was observed between CFH Y402H and DHA-supplementation (p=0.01). We showed a protective effect of DHA-supplementation among homozygous non-risk patients. Among these patients, occurrence of CNV was 38.2% in placebo group versus 16.7% in DHA group (p=0.008).
These results suggest that a genetic predisposition to AMD conferred by the CFH Y402H variant limits the benefit provided by DHA supplementation.
ISRCTN registry 98246501.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0130816</identifier><identifier>PMID: 26132079</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Acids ; Acuity ; Age ; Age related diseases ; Aged ; Alleles ; Antioxidants ; Blood vessels ; Care and treatment ; Comparative studies ; Complement Factor H - genetics ; Confidence intervals ; Dietary Supplements ; Docosahexaenoic acid ; Docosahexaenoic Acids - administration & dosage ; Docosahexaenoic Acids - therapeutic use ; Environmental factors ; Eye ; Fatty acids ; Female ; Fish oils ; Genetic aspects ; Genotypes ; Health risk assessment ; Humans ; Influence ; Lesions ; Macular degeneration ; Macular Degeneration - drug therapy ; Macular Degeneration - genetics ; Male ; Medical research ; Middle Aged ; Omega 3 fatty acids ; Patients ; Physiological aspects ; Polymorphism, Single Nucleotide ; Proteins - genetics ; Randomization ; Risk ; Statistical analysis ; Statistical significance ; Studies ; Tocopherol ; Unsaturated fatty acids ; Visual acuity ; Vitamin E</subject><ispartof>PloS one, 2015-07, Vol.10 (7), p.e0130816-e0130816</ispartof><rights>COPYRIGHT 2015 Public Library of Science</rights><rights>2015 Merle et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Merle et al 2015 Merle et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-12466d2df536bbf176ef6367207669521dd2f8423495648ccd846c30f18b1ccc3</citedby><cites>FETCH-LOGICAL-c692t-12466d2df536bbf176ef6367207669521dd2f8423495648ccd846c30f18b1ccc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489493/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489493/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26132079$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Mori, Keisuke</contributor><creatorcontrib>Merle, Bénédicte M J</creatorcontrib><creatorcontrib>Richard, Florence</creatorcontrib><creatorcontrib>Benlian, Pascale</creatorcontrib><creatorcontrib>Puche, Nathalie</creatorcontrib><creatorcontrib>Delcourt, Cécile</creatorcontrib><creatorcontrib>Souied, Eric H</creatorcontrib><title>CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Genetic susceptibility could be modified by environmental factors and may also influence differential responses to treatments for age-related macular degeneration (AMD). We investigated whether genotype could influence response to docosahexaenoic acid (DHA)-supplementation in the occurrence of choroidal new vessels (CNV).
The Nutritional AMD Treatment 2 (NAT2) study was a randomized, placebo-controlled, double-blind, parallel, comparative study, including 250 patients aged 55 to 85 years with early lesions of age-related maculopathy, visual acuity better than 0.4 Logarithm of Minimum Angle of Resolution units in the study eye and neovascular AMD in the fellow eye. Patients were randomized at baseline to receive either 3 daily fish-oil capsules, each containing 280 mg DHA, 90 mg EPA and 2 mg Vitamin E, or placebo.
Patients carrying the risk allele (C) for CFH Y402H had no statistically significant increased risk for developing CNV in the study eye (Hazard Ratio (HR)=0.97; 95% Confidence Interval (CI): 0.54-1.76 for heterozygous and HR=1.29; 95%CI: 0.69-2.40 for homozygous). Patients carrying the risk allele (T) for ARMS2 A69S had no statistically significant increased risk for developing CNV in the study eye (HR=1.68; 95%CI: 0.91-3.12) for heterozygous and HR=1.78; 95%CI: 0.90-3.52 for homozygous). A significant interaction was observed between CFH Y402H and DHA-supplementation (p=0.01). We showed a protective effect of DHA-supplementation among homozygous non-risk patients. Among these patients, occurrence of CNV was 38.2% in placebo group versus 16.7% in DHA group (p=0.008).
These results suggest that a genetic predisposition to AMD conferred by the CFH Y402H variant limits the benefit provided by DHA supplementation.
ISRCTN registry 98246501.</description><subject>Acids</subject><subject>Acuity</subject><subject>Age</subject><subject>Age related diseases</subject><subject>Aged</subject><subject>Alleles</subject><subject>Antioxidants</subject><subject>Blood vessels</subject><subject>Care and treatment</subject><subject>Comparative studies</subject><subject>Complement Factor H - genetics</subject><subject>Confidence intervals</subject><subject>Dietary Supplements</subject><subject>Docosahexaenoic acid</subject><subject>Docosahexaenoic Acids - administration & dosage</subject><subject>Docosahexaenoic Acids - therapeutic use</subject><subject>Environmental factors</subject><subject>Eye</subject><subject>Fatty acids</subject><subject>Female</subject><subject>Fish oils</subject><subject>Genetic aspects</subject><subject>Genotypes</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Influence</subject><subject>Lesions</subject><subject>Macular degeneration</subject><subject>Macular Degeneration - drug therapy</subject><subject>Macular Degeneration - genetics</subject><subject>Male</subject><subject>Medical research</subject><subject>Middle Aged</subject><subject>Omega 3 fatty acids</subject><subject>Patients</subject><subject>Physiological aspects</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Proteins - genetics</subject><subject>Randomization</subject><subject>Risk</subject><subject>Statistical analysis</subject><subject>Statistical significance</subject><subject>Studies</subject><subject>Tocopherol</subject><subject>Unsaturated fatty acids</subject><subject>Visual acuity</subject><subject>Vitamin E</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9tu1DAQhiMEoqXwBggsISG42CU-xIm5QIpaylbqSd2CxJXltScbV068xElpX4cnxXto1UW9QL4Ya-ab356xJ0le43SMaY4_Xfmha5UbL3wL4xTTtMD8SbKLBSUjTlL69MF-J3kRwlWaZrTg_HmyQzimJM3FbvJn_3CCfrKUTJBqDSovTqYElVxM0bl3t43vFrUNTVgFzzrl0HRYLBw00Paqt75Fv21fowOvfVA13ChovdWo1NYg26JT8Ncq6MGpDpVzGF2AUz0YdKLWvgOYQwvdWuk8migbPqPLGtBpeUnQtB_M7cvkWaVcgFcbu5d8P_x6uT8ZHZ99O9ovj0eaC9KPMGGcG2KqjPLZrMI5h4pTnsc6ORcZwcaQqmCEMpFxVmhtCsY1TStczLDWmu4lb9e6C-eD3LQ3SBzV80zkOI_E0ZowXl3JRWcb1d1Kr6xcOXw3l6rrrXYgsYnXmQmR5gBxA0UuhOIwK4QxudI4an3ZnDbMGjA6Vh7buyW6HWltLef-WjJWCCZoFPiwEej8rwFCLxsbNDinWvDD6t40J1wIHtF3_6CPV7eh5ioWYNvKx3P1UlSWjKSYsSwTkRo_QsVloLE6_sXKRv9WwsethMj0cNPP1RCCPJpe_D979mObff-ArUG5vg7eDcu_FLZBtgZ150PooLpvMk7lcpTuuiGXoyQ3oxTT3jx8oPuku9mhfwG9SxeZ</recordid><startdate>20150701</startdate><enddate>20150701</enddate><creator>Merle, Bénédicte M J</creator><creator>Richard, Florence</creator><creator>Benlian, Pascale</creator><creator>Puche, Nathalie</creator><creator>Delcourt, Cécile</creator><creator>Souied, Eric H</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150701</creationdate><title>CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study</title><author>Merle, Bénédicte M J ; Richard, Florence ; Benlian, Pascale ; Puche, Nathalie ; Delcourt, Cécile ; Souied, Eric H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-12466d2df536bbf176ef6367207669521dd2f8423495648ccd846c30f18b1ccc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Acids</topic><topic>Acuity</topic><topic>Age</topic><topic>Age related diseases</topic><topic>Aged</topic><topic>Alleles</topic><topic>Antioxidants</topic><topic>Blood vessels</topic><topic>Care and treatment</topic><topic>Comparative studies</topic><topic>Complement Factor H - genetics</topic><topic>Confidence intervals</topic><topic>Dietary Supplements</topic><topic>Docosahexaenoic acid</topic><topic>Docosahexaenoic Acids - administration & dosage</topic><topic>Docosahexaenoic Acids - therapeutic use</topic><topic>Environmental factors</topic><topic>Eye</topic><topic>Fatty acids</topic><topic>Female</topic><topic>Fish oils</topic><topic>Genetic aspects</topic><topic>Genotypes</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Influence</topic><topic>Lesions</topic><topic>Macular degeneration</topic><topic>Macular Degeneration - drug therapy</topic><topic>Macular Degeneration - genetics</topic><topic>Male</topic><topic>Medical research</topic><topic>Middle Aged</topic><topic>Omega 3 fatty acids</topic><topic>Patients</topic><topic>Physiological aspects</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Proteins - genetics</topic><topic>Randomization</topic><topic>Risk</topic><topic>Statistical analysis</topic><topic>Statistical significance</topic><topic>Studies</topic><topic>Tocopherol</topic><topic>Unsaturated fatty acids</topic><topic>Visual acuity</topic><topic>Vitamin E</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Merle, Bénédicte M J</creatorcontrib><creatorcontrib>Richard, Florence</creatorcontrib><creatorcontrib>Benlian, Pascale</creatorcontrib><creatorcontrib>Puche, Nathalie</creatorcontrib><creatorcontrib>Delcourt, Cécile</creatorcontrib><creatorcontrib>Souied, Eric H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Merle, Bénédicte M J</au><au>Richard, Florence</au><au>Benlian, Pascale</au><au>Puche, Nathalie</au><au>Delcourt, Cécile</au><au>Souied, Eric H</au><au>Mori, Keisuke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2015-07-01</date><risdate>2015</risdate><volume>10</volume><issue>7</issue><spage>e0130816</spage><epage>e0130816</epage><pages>e0130816-e0130816</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Genetic susceptibility could be modified by environmental factors and may also influence differential responses to treatments for age-related macular degeneration (AMD). We investigated whether genotype could influence response to docosahexaenoic acid (DHA)-supplementation in the occurrence of choroidal new vessels (CNV).
The Nutritional AMD Treatment 2 (NAT2) study was a randomized, placebo-controlled, double-blind, parallel, comparative study, including 250 patients aged 55 to 85 years with early lesions of age-related maculopathy, visual acuity better than 0.4 Logarithm of Minimum Angle of Resolution units in the study eye and neovascular AMD in the fellow eye. Patients were randomized at baseline to receive either 3 daily fish-oil capsules, each containing 280 mg DHA, 90 mg EPA and 2 mg Vitamin E, or placebo.
Patients carrying the risk allele (C) for CFH Y402H had no statistically significant increased risk for developing CNV in the study eye (Hazard Ratio (HR)=0.97; 95% Confidence Interval (CI): 0.54-1.76 for heterozygous and HR=1.29; 95%CI: 0.69-2.40 for homozygous). Patients carrying the risk allele (T) for ARMS2 A69S had no statistically significant increased risk for developing CNV in the study eye (HR=1.68; 95%CI: 0.91-3.12) for heterozygous and HR=1.78; 95%CI: 0.90-3.52 for homozygous). A significant interaction was observed between CFH Y402H and DHA-supplementation (p=0.01). We showed a protective effect of DHA-supplementation among homozygous non-risk patients. Among these patients, occurrence of CNV was 38.2% in placebo group versus 16.7% in DHA group (p=0.008).
These results suggest that a genetic predisposition to AMD conferred by the CFH Y402H variant limits the benefit provided by DHA supplementation.
ISRCTN registry 98246501.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>26132079</pmid><doi>10.1371/journal.pone.0130816</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2015-07, Vol.10 (7), p.e0130816-e0130816 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1692759717 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Acids Acuity Age Age related diseases Aged Alleles Antioxidants Blood vessels Care and treatment Comparative studies Complement Factor H - genetics Confidence intervals Dietary Supplements Docosahexaenoic acid Docosahexaenoic Acids - administration & dosage Docosahexaenoic Acids - therapeutic use Environmental factors Eye Fatty acids Female Fish oils Genetic aspects Genotypes Health risk assessment Humans Influence Lesions Macular degeneration Macular Degeneration - drug therapy Macular Degeneration - genetics Male Medical research Middle Aged Omega 3 fatty acids Patients Physiological aspects Polymorphism, Single Nucleotide Proteins - genetics Randomization Risk Statistical analysis Statistical significance Studies Tocopherol Unsaturated fatty acids Visual acuity Vitamin E |
| title | CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T08%3A04%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CFH%20Y402H%20and%20ARMS2%20A69S%20Polymorphisms%20and%20Oral%20Supplementation%20with%20Docosahexaenoic%20Acid%20in%20Neovascular%20Age-Related%20Macular%20Degeneration%20Patients:%20The%20NAT2%20Study&rft.jtitle=PloS%20one&rft.au=Merle,%20B%C3%A9n%C3%A9dicte%20M%20J&rft.date=2015-07-01&rft.volume=10&rft.issue=7&rft.spage=e0130816&rft.epage=e0130816&rft.pages=e0130816-e0130816&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0130816&rft_dat=%3Cgale_plos_%3EA420144559%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1692759717&rft_id=info:pmid/26132079&rft_galeid=A420144559&rft_doaj_id=oai_doaj_org_article_1d246b9907ee46be8799a6eb89dd7ac1&rfr_iscdi=true |